What is MEIHUA INTL MED TECH CO's earnings per share (EPS)?

MEIHUA INTL MED TECH CO (MHUAF) reported diluted earnings per share of $18.04 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

MEIHUA INTL MED TECH CO (MHUAF) Financials

MHUAF

FY2025 annual

Revenue $61.8M -36.2% YoY

Net Income $6.8M -37.5% YoY

EPS (Diluted) $18.04 YoY not available

Free Cash Flow $554K -96.2% YoY

Market Cap $6.0M as of Sep 3, 2026

Price / Sales 0.1x on $61.8M revenue, FY2025

Price / Earnings 0.9x on $6.8M net income, FY2025

Price / Book 0.0x on $188.9M equity, Q4 FY2025

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period FY2025, ended Dec 31, 2025 Reported Apr 29, 2026 Currency USD FYE December

Newest figures come from the 10-K for FY2025, filed Apr 29, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MHUAF SEC filings page.

MEIHUA INTL MED TECH CO (MHUAF) reported $61.8M in revenue for fiscal year 2025, down 36.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI MHUAF FY2025 2026-08-30

Revenue contraction is exposing a cash-conversion and capital-allocation shift despite a balance sheet becoming more liquid.

In FY2025, cash conversion weakened far more than reported profit: net income was $6.8M, but operating cash flow was only $570K. With capex at just $16K, free cash flow of $554K indicates the cash shortfall was not driven by fixed-asset reinvestment, pointing instead to operating or working-capital absorption.

Revenue contracted in FY2025 while gross margin fell from 34.4% to 31.0%, showing that weaker scale was accompanied by less favorable economics rather than being purely a volume event. Operating margin narrowed to 13.4% even as selling, general and administrative expense was lower, indicating cost reduction did not fully absorb the contraction.

Balance-sheet resilience increased: liabilities fell 33.0% while assets rose 11.2%, making the capital structure less debt-dependent. The current ratio reached 8.4x, but current assets included $84.3M of receivables versus only $1.7M of inventory, so liquidity depends more on collections than stock turnover.

Financial Health Signals

Financial health score not available

MEIHUA INTL MED TECH CO does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Grey Zone

2.17

MEIHUA INTL MED TECH CO scores 2.17, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/8

MEIHUA INTL MED TECH CO passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Low Quality

0.08x

For every $1 of reported earnings, MEIHUA INTL MED TECH CO generates $0.08 in operating cash flow ($570K OCF vs $6.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage Safe

34.30x

MEIHUA INTL MED TECH CO earns $34.30 in operating income for every $1 of interest expense ($8.3M vs $242K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

None of these metrics is reported for Q4 2025.

Cash & Balance Sheet

Cash & Debt

$15.2M

YoY-12.3%

QoQ-10.3%

MEIHUA INTL MED TECH CO held $15.2M in cash as of Q4 2025; long-term debt is not reported for that period.

Shares Outstanding

697,914

MEIHUA INTL MED TECH CO had 697,914 shares outstanding in Q4 2025.

Free Cash Flow

Not reported for Q4 2025.

Dividends Per Share

Not reported for Q4 2025.

Margins & Returns

None of these metrics is reported for Q4 2025.

Capital Allocation

None of these metrics is reported for Q4 2025.

MHUAF Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MHUAF quarterly income statement

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K
Revenue	$61.8M-36.2%	$96.9M-0.2%	$97.1M-6.0%	$103.3M-0.7%	$104.0M+16.8%	$89.1M+11.8%	$79.6M
Cost of Revenue	$42.6M-33.0%	$63.6M-0.5%	$63.9M-2.1%	$65.2M+1.6%	$64.2M+23.8%	$51.9M+9.5%	$47.4M
Gross Profit	$19.2M-42.5%	$33.3M+0.3%	$33.2M-12.9%	$38.1M-4.3%	$39.8M+7.1%	$37.2M+15.4%	$32.2M
R&D Expenses	$2.4M-31.0%	$3.5M+25.5%	$2.8M-7.1%	$3.0M+8.7%	$2.7M+9.3%	$2.5M-22.5%	$3.2M
SG&A Expenses	$3.2M-58.7%	$7.8M+19.0%	$6.5M-47.5%	$12.5M+185.9%	$4.4M-4.7%	$4.6M+8.9%	$4.2M
Operating Income	$8.3M-42.1%	$14.3M-2.5%	$14.7M+35.9%	$10.8M-58.9%	$26.3M+11.9%	$23.5M+21.0%	$19.4M
EBITDA	$8.8M-40.6%	$14.9M-1.7%	$15.1M+33.5%	$11.3M-57.8%	$26.9M+12.1%	$24.0M+20.6%	$19.9M
Interest Expense	$242K-2.5%	$248K-1.3%	$251K+31.2%	$191K+5.8%	$181K+31.8%	$137K+40.3%	$98K
Income Tax	$2.6M-5.9%	$2.8M-19.3%	$3.5M-26.6%	$4.7M-10.7%	$5.3M+12.6%	$4.7M+22.8%	$3.8M
Net Income	$6.8M-37.5%	$10.8M-6.7%	$11.6M+86.2%	$6.2M-70.2%	$20.9M+10.0%	$19.0M+23.4%	$15.4M
EPS (Basic)	$18.04-54.5%	$39.62-18.4%	$48.56+17885.2%	$0.27-74.3%	$1.05+10.5%	$0.95+14.5%	$0.83
EPS (Diluted)	$18.04	$39.62-18.4%	$48.56	$0.27-74.3%	$1.05+10.5%	$0.95	N/A
Diluted Shares (Avg)	376,035	273,717+14.3%	239,400	23M+17.1%	20M0.0%	20M	N/A

Metric	Q4'2510-K	Q2'2510-Q	Q4'2410-K	Q2'2410-Q	Q4'2310-K	Q2'2310-Q	Q4'2210-K	Q4'2110-K

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).

MHUAF Balance Sheet

MHUAF quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K
Total Assets	$207.2M+11.2%	$186.2M+8.3%	$171.9M+5.1%	$163.6M+19.5%	$136.9M+29.1%	$106.0M	N/A
Current Assets	$153.6M+7.1%	$143.4M+8.5%	$132.2M-2.3%	$135.3M+39.1%	$97.3M+44.0%	$67.6M	N/A
Cash & Equivalents	$15.2M-12.3%	$17.3M+2.1%	$16.9M-36.7%	$26.7M+228.1%	$8.1M+13.4%	$7.2M-55.2%	$16.0M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0
Inventory	$1.7M+20.9%	$1.4M-12.8%	$1.6M+44.1%	$1.1M-10.3%	$1.3M-5.6%	$1.3M	N/A
Accounts Receivable	$84.3M+7.2%	$78.7M+0.1%	$78.6M+14.0%	$68.9M+2.7%	$67.1M+46.8%	$45.7M	N/A
Long-Term Investments	$23.5M+4.7%	$22.4M+265.1%	$6.1M-8.1%	$6.7M+608.4%	$942K+2.4%	$920K	$0
Goodwill	N/A	$7.9M	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$18.3M-33.1%	$27.3M+8.7%	$25.1M+0.7%	$24.9M-14.4%	$29.1M+36.5%	$21.3M	N/A
Current Liabilities	$18.3M-33.1%	$27.3M+8.7%	$25.1M+3.7%	$24.2M-16.9%	$29.1M+36.5%	$21.3M	N/A
Non-Current Liabilities	$0	$0-100.0%	$5K-99.4%	$725K	$0	$0	N/A
Long-Term Debt	N/A	N/A	N/A	$725K	N/A	N/A	N/A
Total Equity	$188.9M+18.8%	$159.0M+8.6%	$146.3M+5.9%	$138.1M+28.2%	$107.8M+27.2%	$84.7M+42.0%	$59.7M
Retained Earnings	$111.9M+6.4%	$105.2M+11.2%	$94.6M+13.6%	$83.3M+7.4%	$77.6M+37.0%	$56.6M	N/A

Metric	Q4'2510-K	Q2'2510-Q	Q4'2410-K	Q2'2410-Q	Q4'2310-K	Q2'2310-Q	Q4'2210-K	Q4'2110-K
Total Assets	$207.2M+11.2%	$190.6M+6.4%	$186.2M+8.3%	$179.2M+10.2%	$171.9M+5.1%	$162.6M	$163.6M+19.5%	$136.9M+29.1%
Current Assets	$153.6M+7.1%	$146.3M+3.6%	$143.4M+8.5%	$141.3M+6.8%	$132.2M-2.3%	$132.3M	$135.3M+39.1%	$97.3M+44.0%
Cash & Equivalents	$15.2M-12.3%	$16.9M-8.6%	$17.3M+2.1%	$18.5M+3.5%	$16.9M-36.7%	$17.9M	$26.7M+228.1%	$8.1M+13.4%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$1.7M+20.9%	$1.1M+0.8%	$1.4M-12.8%	$1.1M-33.7%	$1.6M+44.1%	$1.6M	$1.1M-10.3%	$1.3M-5.6%
Accounts Receivable	$84.3M+7.2%	$86.6M+4.9%	$78.7M+0.1%	$82.6M+4.4%	$78.6M+14.0%	$79.1M	$68.9M+2.7%	$67.1M+46.8%
Long-Term Investments	$23.5M+4.7%	$22.9M+164.7%	$22.4M+265.1%	$8.6M+44.1%	$6.1M-8.1%	$6.0M	$6.7M+608.4%	$942K+2.4%
Goodwill	N/A	N/A	$7.9M	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$18.3M-33.1%	$25.6M-13.4%	$27.3M+8.7%	$29.6M+27.4%	$25.1M+0.7%	$23.2M	$24.9M-14.4%	$29.1M+36.5%
Current Liabilities	$18.3M-33.1%	$25.6M-13.4%	$27.3M+8.7%	$29.6M+27.4%	$25.1M+3.7%	$23.2M	$24.2M-16.9%	$29.1M+36.5%
Non-Current Liabilities	$0	$0	$0-100.0%	$0	$5K-99.4%	$0	$725K	$0
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	$725K	N/A
Total Equity	$188.9M+18.8%	$164.9M+10.3%	$159.0M+8.6%	$149.6M+7.7%	$146.3M+5.9%	$138.9M	$138.1M+28.2%	$107.8M+27.2%
Retained Earnings	$111.9M+6.4%	$108.3M+9.1%	$105.2M+11.2%	$99.3M+9.8%	$94.6M+13.6%	$90.4M	$83.3M+7.4%	$77.6M+37.0%

MHUAF Cash Flow Statement

MHUAF quarterly cash flow statement

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K
Operating Cash Flow	$570K-96.1%	$14.6M+543.2%	$2.3M+124.8%	-$9.2M-16662.8%	-$55K-101.0%	$5.3M-42.8%	$9.3M
Depreciation & Amortization	$549K-3.7%	$571K+21.3%	$470K-13.1%	$541K-9.1%	$596K+19.8%	$497K+3.4%	$481K
Capital Expenditures	$16K-88.3%	$134K-88.7%	$1.2M-56.2%	$2.7M+217.4%	$850K-77.7%	$3.8M+1327.7%	$267K
Free Cash Flow	$554K-96.2%	$14.5M+1226.9%	$1.1M+109.2%	-$11.9M-1210.8%	-$905K-159.6%	$1.5M-83.2%	$9.0M
Investing Cash Flow	-$20.1M+1.4%	-$20.4M-63.9%	-$12.5M-44.5%	-$8.6M-933.8%	-$834K+94.8%	-$16.1M-80.8%	-$8.9M
Financing Cash Flow	$17.2M+176.7%	$6.2M+780.0%	$706K-98.1%	$37.2M+1902.2%	$1.9M+9.0%	$1.7M+84.8%	$924K
Share Buybacks	N/A	$200K	N/A	N/A	N/A	N/A	N/A

Metric	Q4'2510-K	Q2'2510-Q	Q4'2410-K	Q2'2410-Q	Q4'2310-K	Q2'2310-Q	Q4'2210-K	Q4'2110-K

Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.

MHUAF Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MHUAF quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K
Gross Margin	31.0%-3.4pp	34.4%+0.2pp	34.2%-2.7pp	36.9%-1.4pp	38.3%-3.5pp	41.7%+1.3pp	40.5%
Operating Margin	13.4%-1.4pp	14.8%-0.3pp	15.1%+4.7pp	10.4%-14.8pp	25.2%-1.1pp	26.4%+2.0pp	24.3%
Net Margin	11.0%-0.2pp	11.2%-0.8pp	12.0%+5.9pp	6.0%-14.1pp	20.1%-1.2pp	21.4%+2.0pp	19.4%
Return on Equity	3.6%-3.2pp	6.8%-1.1pp	7.9%+3.4pp	4.5%-14.9pp	19.4%-3.0pp	22.5%-3.4pp	25.9%
Return on Assets	3.3%-2.6pp	5.8%-0.9pp	6.8%+2.9pp	3.8%-11.5pp	15.3%-2.6pp	18.0%	N/A
Current Ratio	8.41+3.2x	5.260.0x	5.27-0.3x	5.60+2.3x	3.34+0.2x	3.17	N/A
Debt-to-Equity	0.10-0.1x	0.170.0x	0.17+0.2x	0.01-0.3x	0.270.0x	0.25	N/A
Asset Turnover	0.30-0.2x	0.520.0x	0.56-0.1x	0.63-0.1x	0.76-0.1x	0.84	N/A
FCF Margin	0.9%-14.1pp	15.0%+13.8pp	1.1%+12.6pp	-11.5%-10.6pp	-0.9%-2.6pp	1.7%-9.7pp	11.4%

Metric	Q4'2510-K	Q2'2510-Q	Q4'2410-K	Q2'2410-Q	Q4'2310-K	Q2'2310-Q	Q4'2210-K	Q4'2110-K
Current Ratio	8.41+3.2x	5.71+0.9x	5.260.0x	4.78-0.9x	5.27-0.3x	5.70	5.60+2.3x	3.34+0.2x
Debt-to-Equity	0.10-0.1x	0.160.0x	0.170.0x	0.200.0x	0.17+0.2x	0.17	0.01-0.3x	0.270.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.

Where MEIHUA INTL MED TECH CO Ranks

Frequently Asked Questions

What is MEIHUA INTL MED TECH CO's annual revenue?

MEIHUA INTL MED TECH CO (MHUAF) reported $61.8M in total revenue for fiscal year 2025. This represents a -36.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is MEIHUA INTL MED TECH CO's revenue growing?

MEIHUA INTL MED TECH CO (MHUAF) revenue declined by 36.2% year-over-year, from $96.9M to $61.8M in fiscal year 2025.

Is MEIHUA INTL MED TECH CO profitable?

Yes, MEIHUA INTL MED TECH CO (MHUAF) reported a net income of $6.8M in fiscal year 2025, with a net profit margin of 11.0%.

What is MEIHUA INTL MED TECH CO's EBITDA?

MEIHUA INTL MED TECH CO (MHUAF) had EBITDA of $8.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is MEIHUA INTL MED TECH CO's gross margin?

MEIHUA INTL MED TECH CO (MHUAF) had a gross margin of 31.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is MEIHUA INTL MED TECH CO's operating margin?

MEIHUA INTL MED TECH CO (MHUAF) had an operating margin of 13.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is MEIHUA INTL MED TECH CO's net profit margin?

MEIHUA INTL MED TECH CO (MHUAF) had a net profit margin of 11.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is MEIHUA INTL MED TECH CO's return on equity (ROE)?

MEIHUA INTL MED TECH CO (MHUAF) has a return on equity of 3.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is MEIHUA INTL MED TECH CO's free cash flow?

MEIHUA INTL MED TECH CO (MHUAF) generated $554K in free cash flow during fiscal year 2025. This represents a -96.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is MEIHUA INTL MED TECH CO's operating cash flow?

MEIHUA INTL MED TECH CO (MHUAF) generated $570K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are MEIHUA INTL MED TECH CO's total assets?

MEIHUA INTL MED TECH CO (MHUAF) had $207.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are MEIHUA INTL MED TECH CO's capital expenditures?

MEIHUA INTL MED TECH CO (MHUAF) invested $16K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does MEIHUA INTL MED TECH CO spend on research and development?

MEIHUA INTL MED TECH CO (MHUAF) invested $2.4M in research and development during fiscal year 2025.

How many shares does MEIHUA INTL MED TECH CO have outstanding?

MEIHUA INTL MED TECH CO (MHUAF) had 697,914 shares outstanding as of fiscal year 2025.

What is MEIHUA INTL MED TECH CO's current ratio?

MEIHUA INTL MED TECH CO (MHUAF) had a current ratio of 8.41 as of fiscal year 2025, which is generally considered healthy.

What is MEIHUA INTL MED TECH CO's debt-to-equity ratio?

MEIHUA INTL MED TECH CO (MHUAF) had a debt-to-equity ratio of 0.10 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is MEIHUA INTL MED TECH CO's return on assets (ROA)?

MEIHUA INTL MED TECH CO (MHUAF) had a return on assets of 3.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is MEIHUA INTL MED TECH CO's P/E ratio?

MEIHUA INTL MED TECH CO (MHUAF) trades at 0.9x earnings, its market capitalization divided by net income of $6.8M net income, FY2025. The market capitalization is $6.0M as of Sep 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is MEIHUA INTL MED TECH CO's price-to-sales ratio?

MEIHUA INTL MED TECH CO (MHUAF) trades at 0.1x sales, its market capitalization divided by revenue of $61.8M revenue, FY2025. The market capitalization is $6.0M as of Sep 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is MEIHUA INTL MED TECH CO's Altman Z-Score?

MEIHUA INTL MED TECH CO (MHUAF) has an Altman Z-Score of 2.17, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is MEIHUA INTL MED TECH CO's Piotroski F-Score?

MEIHUA INTL MED TECH CO (MHUAF) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are MEIHUA INTL MED TECH CO's earnings high quality?

MEIHUA INTL MED TECH CO (MHUAF) has an earnings quality ratio of 0.08x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can MEIHUA INTL MED TECH CO cover its interest payments?

MEIHUA INTL MED TECH CO (MHUAF) has an interest coverage ratio of 34.30x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.